Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its Phase 2 Advance-HTN trial data will be presented during a late-breaking clinical trials session at the American College of …
Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials evaluating lorundrostat for the treatment of uncontrolled …
Mineralys Reports Positive Results for Hypertension Drug Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has scheduled a conference call and webinar on Monday, March 10, 2025, at 8:00 a.m. ET to present topline results from its …
Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported its financial results for the fourth quarter and full year ending December 31, 2024, while sharing significant updates on the development of …
Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company, will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 12, 2025, before the market opens.
Mineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial Results Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the completion of enrollment for its Explore-CKD Phase 2 trial. The study is evaluating the efficacy and safety of lorundrostat, …
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial Read More RADNOR, PA — Mineralys Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 2 clinical trial …
Mineralys Therapeutics Receives FDA Clearance for Phase 2 Trial of Lorundrostat in Treating Sleep Apnea and Hypertension Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has released its financial results for the third quarter ending September 30, 2024, alongside key updates on its clinical trials. The company …
Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is gearing up to participate in a series of fireside chats at notable investor conferences this fall. These events provide an opportunity …
Mineralys Therapeutics Set to Engage with Investors at Key Conferences Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the swift completion of participant enrollment in its Launch-HTN trial, a critical component of its pivotal program investigating lorundrostat for the …
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial Read More